Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy
Bingshe Han(Chinese Academy of Medical Sciences & Peking Union Medical College), Xingming Deng(Emory University), Guojing Zhang(Emory University), Jia Zhou(Io Therapeutics (United States)), Gabriel Sica(Emory University), Walter J. Curran(Piedmont Cancer Institute), Andrew T. Magis(Institute for Systems Biology), Dongkyoo Park(Central South University), Fadlo R. Khuri(American University of Beirut Medical Center), Chunyong Ding(Shanghai Jiao Tong University), Zhuo G. Chen(Emory University), Suresh S. Ramalingam(Emory University), Rui Li(Henan Cancer Hospital), Dong M. Shin(Emory University), Maohua Xie(Central South University), Taofeek K. Owonikoko(UPMC Hillman Cancer Center)
Cited by 136
Related Papers
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
|The Lancet|2004|2.4k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k